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A B S T R A C T
Tenatumomab is an anti-tenascin murine monoclonal antibody previously used in clinical trials for delivering
radionuclides to tumors by both pre-targeting (biotinylated Tenatumomab within PAGRIT) and direct 131Iodine
labeling approaches. Here we present the synthesis and in vitro characterization of three Tenatumomab con-
jugates to bifunctional chelating agents (NHS-DOTA, NCS-DOTA and NCS-DTPA). Results indicate ST8198AA1
(Tenatumomab-DOTAMA, derived by conjugation of NHS-DOTA), as the most promising candidate in terms of
conjugation rate and yield, stability, antigen immunoreactivity and affinity. Labeling efficiency of the different
chelators was investigated with a panel of cold metals indicating DOTAMA as the best chelator. Labeling of
Tenatumomab-DOTAMA was then optimized with several metals and stability performed confirms suitability of
this conjugate for further development. ST8198AA1 represents an improvement of the previous antibody forms
because the labeling with radionuclides like 177Lu or 64Cu would allow theranostic applications in patients
bearing tenascin expressing tumors.
1. Introduction
Tenascin-C is a hexameric glycoprotein found in embryonic and
adult extracellular matrices.1 It can undergo alternative splicing re-
sulting in large (monomer>320 kDa) or small (monomer<220 kDa)
isoforms. The large Tenascin-C variant is preferentially expressed in
malignant solid2–7 and hematological tumors.8 It is spatially and tem-
porally related to tumor neovascularization and may exert anti-ad-
hesive, and immunosuppressive activities. The presence of Tenascin-C
within tumor-infiltrated tissues made it as an attractive candidate for
antibody mediated therapy.
“Theranostic” or sometime named “theragnostic” is a neologism
used in the last decade, which combines the words “therapeutic” and
“diagnostic” for drugs or methods concerning the possibility of ex-
ploiting them both in therapeutic indications and for diagnostic appli-
cations. In this paper we have used the term theranostic because the
results here reported could allow the use of this conjugate both in the
therapeutic and diagnostic field. In detail, Tenatumomab (ST2146) is a
murine monoclonal antibody recognizing the extra-cellular matrix
protein Tenascin-C. It was originally imagined to deliver radionuclide
therapy to tumors9–11 and in its biotinylated version, proved to be
useful for targeting radioactive biotin (90Yttrium-BiotinDOTA) ac-
cording to Pre-targeted Antibody Guided RadioImmunoTherapy (PA-
GRIT) clinical protocol.12 Nevertheless, because such procedure re-
quires the simultaneous production of multiple drugs, it was deemed
too cumbersome to be pursued industrially and therefore the develop-
ment of PAGRIT was discontinued in favor of simpler Tenatumomab
versions. A clinical trial with 131Iodine-Tenatumomab, in Tenascin-C
positive cancer patients, was started but preliminary results suggested
revising infusion modality (ClinicalTrials.gov NCT02602067) pointing
out the need of an imaging guided approach to personalize treatment.
In fact, despite fine specificity, monoclonal antibodies display inter-
individual variability due to unpredictable factors like Fc receptor af-
finity, level of circulating antigen or presence of Anti-Drug Antibodies
(ADA), thus requiring patient-specific information on the antibody
distribution to personalize the radiotherapeutic treatment.13,14
Targeted radionuclide therapy (TRT) is a promising technique for
cancer therapy but, so far, only 90Y/111In-Ibritumomab tiuxetan
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(Zevalin, Biogen IDEC) survived on the market for the therapy of Non-
Hodgkin Lymphoma (NHL). The labeling of monoclonal antibodies with
suitable radionuclides for SPECT and PET imaging and cancer therapy
is an approach known as theranostic.15 More than 20 antibodies or
antibody-related therapeutics are currently investigated for theranostic
purposes in patients.16 In line with this trend, here we describe the
chemical conjugation of three chelator moieties to Tenatumomab and
the preliminary characterization of the related derivatives in a pro-
spective theranostic use.
2. Results and discussion
2.1. Synthesis of cyclohexylamine-conjugated chelators
We started this study with the preparation of model compounds
from four commercial bifunctional chelating agents (BFCAs), based on
DOTA (1,4,7,10-tetraazacyclododecane tetraacetic acid), DTPA (die-
thylenetriamine pentaacetic acid) and NOTA (1,4,7-triazacyclononane
triacetic acid) structures (Scheme 1).17 These BFCAs were reacted with
cyclohexylamine to mimic the bond formed in the conjugation of these
ligands with antibody’s external lysines (Scheme 1S). The reaction
products thus formed were isolated in 55–75% yield, characterized by
1H, 13C NMR and HPLC-MS (see SI for details).
2.2. Complexation and preliminary stability of the model complexes
Each model chelator compound was complexed with 5 different
metal ions: In(III), Y(III), Lu(III), Gd(III) and Cu(II). The Cu(II) complex
with Cy-Bn-DOTA could not be further studied since a precipitate was
formed immediately after addition of the metal ion to the ligand solu-
tion at three different pH (4–6). It is well established that the kinetic
inertness of Ln(III) complexes is generally assessed either by measuring
the rate of their dissociation under very acidic conditions or by de-
termining the rate of transmetallation reaction, occurring in solution
with competing Zn2+ or Cu2+ ions.18 However, we focused here on
testing the stability of the complexes under physiological conditions
(PBS buffer at pH 7.4 and at 37 °C), by HPLC–MS, verifying that no
further peaks were formed every day for seven days. In the case of
diamagnetic metals, a further study was carried out via 1H NMR,
maintaining the solution in D2O at 37 °C for one week. In the case of Gd
(III), relaxivity was measured every day to determine its variation over
time as an indication of the stability of the complex (if free Gd3+ ion
was released, the relaxivity would increase over time).
Under these conditions, all the complexes resulted stable except
LnNOTA-like complexes, as expected due to the presence of only six
donor atoms in this chelator. In particular, a peak in the LC–MS chro-
matogram correspondent to the free ligand was clearly detectable after
24 h for the Y(III), Gd(III) and Lu(III) complexes of Cy-Bn-NOTA and
after 72 h only 25% of the complex remained intact (see S.I., Figs. S1
and S2). Thus, after these preliminary tests, we decided to continue the
study with the antibody conjugates with all BFCAs except p-SCN-Bn-
NOTA.
2.3. Synthesis of the mAb-ligand conjugates
Between the different conjugates, NHS-DOTA showed higher re-
activity compared to the other chelating agents used. In fact, it was
sufficient a 10-fold molar excess and 45min of reaction time to obtain a
Chelator-Antibody-Ratio (CAR) in the desired range (CAR∼2). A 20-
fold molar excess and two hours of reaction time were needed for p-
SCN-Bn-DOTA and p-SCN-Bn-CHX-A″-DTPA to obtain similar ratios. No
improvements were observed, in general, heating the reaction mixtures.
2.4. mAb-chelator conjugates analysis by MALDI
The comparison between the MALDI mass spectra of the naked
Tenatumomab and each of the conjugated derivatives, NHS-DOTA, p-
SCN-Bn-DOTA and p-SCN-Bn-CHX-A″-DTPA, showed an averaged CAR
of 2.3, 1.8 and 2.3, respectively. The conjugation reactions were per-
formed in triplicate and the molecular weight of the products averaged.
In order to get information on the localization of the chelating agent
on the mAb, Tenatumomab and its derivatives were reduced with tris-
(2-carboxyethyl)phosphine (TCEP) and analyzed by MALDI mass
spectrometry. The results obtained showed unchanged molecular
weight (at about 24 kDa) for the light chain of both the naked and the
NHS-DOTA conjugated product (Tenatumomab-DOTAMA), while for
the NCS derivatives also a molecular species with increased molecular
weight was observed; the mass shift was attributed to the presence of
one molecule of the chelating agent (Fig. S3).
For all the compounds, the heavy chain showed a difference in
molecular weight attributable to the presence of one molecule of che-
lating agent conjugated except for Tenatumomab-DOTAMA. In fact, for
the latter, the heavy chain of the unconjugated antibody was 51.9 kDa,
while the derivative was 52.4 kDa. The difference was about 500 Da,
corresponding to two DOTA residues (Fig. S4). From these data, it can
be hypothesized that the conjugation reactions occurred preferentially
on the heavy chain of the antibody, but, in the case of isothiocyanate,
also conjugation to the light chain was possible.
2.5. Complexation of Tenatumomab-conjugates with metals ions, and
stability
For the conjugates, antibody-chelator Tenatumomab-(DOTAMA),
Tenatumomab-(Bn-DOTA) and Tenatumomab-(Bn-CHX-A″-DTPA),
complexed with excess In3+, Y3+, Lu3+ ions (ratio metal:conjugate 5:1)
in acetate buffer at pH 5.0, the results are summarized in Table 1.
Scheme 1. Bifunctional chelating agents used in this work.
Table 1
Yields of the complexation of Tenatumomab-chelator conjugates with In3+,
Y3+, Cu2+ and Lu3+ (ratio MAb-chelator/metal ion 1:5) in 0.2M acetate
buffer, pH 5 and 37 °C and stability of the complexes over 7 days.
Entry MAb-ML Yield (%) Stability after
7 day in PBS at
37 °C (%)
1 Tenatumomab-In(DOTAMA) 22 99.2
2 Tenatumomab-[In(Bn-CHX-A″-DTPA)]2− 100 99.8
3 Tenatumomab-[In(Bn-DOTA)]− 31 99.0
4 Tenatumomab-Y(DOTAMA) 37 99.3
5 Tenatumomab-[Y(Bn-CHX-A″-DTPA)]2− 15 96.9
6 Tenatumomab-[Y(Bn-DOTA)]− 50 99.2
7 Tenatumomab-Lu(DOTAMA) 100 98.0
8 Tenatumomab-[Lu(Bn-CHX-A″-DTPA)]2− 25 99.6
9 Tenatumomab-[Lu(Bn-DOTA)]− 48 88.7
10 Tenatumomab-Cu(DOTAMA) 100 95.5
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In particular, unlike the model systems discussed earlier, the yields
are not always quantitative. Indeed, for some complexes, the yield of
complexation was found to be less than 50%, while for others the yield
varies between 50 and 80%. Only three complexes were obtained with a
quantitative yield. With regard to the stability measurements, a free
metal release after one week was lower than 1% for most of the com-
plexes.
Clearly, the model system cannot be coincident with the antibody-
chelator system in which the concentrations involved are different and
the buffer has a possible influence. Since the concentration of the
radiometals during the labeling is supposedly much lower than that of
the chelator (conjugate:metal ratio of 1:0.1), an assessment of complex
stability was not considered necessary. The yields of complexation were
carried out in triplicate. In the case of the Tenatumomab-DOTAMA
conjugate, the Cu2+ complex was also prepared in the two selected
buffers. The complexation yield was then determined via ICP-MS
(Table 2).
The data reported in Table 2 shows that the Lu(Bn-DOTA) complex
in Hepes buffer was virtually not formed (yield of 0.2%). It can be noted
that for Lu(III) the synthesis in acetate buffer at pH 5 is preferable with
respect to the Hepes buffer at pH 6.8 (as also reported in the litera-
ture),19 whereas for the other metal ions the yields are typically higher
in Hepes buffer at pH 6.8.
The stability of the conjugates of Tenatumomab with NHS-DOTA
(ST8198AA1), NCS-DOTA (ST8199AA1) and NCS-DTPA (ST8200AA1)
was investigated by SEC-HPLC analysis, incubating the conjugates in
PBS at 37 or 56 °C up to 24 h. Molecular integrity was then evaluated by
size exclusion chromatography in comparison with unconjugated
Tenatumomab. Results show no significant change in chromatography
profiles of all conjugates incubated at 37 °C while both Tenatumomab
and conjugates were degraded at 56 °C (Fig. S5).
2.6. Surface plasmon resonance (SPR) results
Surface plasmon resonance (SPR) spectroscopy was applied to in-
vestigate kinetics parameter for interaction of Tenatumomab and its
conjugates with Tenascin-C. Analysis of sensorgrams (see S.I. Figs.
S6–S9) shows that best fitting is achieved by a bivalent model. All four
antibodies (Tenatumomab and three conjugates to bifunctional che-
lating agents), however, show a dissociation from Tenascin-C almost
insignificant (for kinetic data from fitting and fitted sensorgrams see S.I.
Figs. S6–S9 and Table S1).
This makes it difficult to consider the dissociation data obtained as
reliable, so we focused our attention on association region of sensor-
grams. As it is possible to see in Fig. 1A, association constant ka1 of
ST8198AA1 is quite similar to that of ST2146, while ST8199AA1 and
ST8200AA1 ka1 constants are about seven time smaller than that of
ST2146. Four sensorgrams (Fig. 1B) for relative Abs tested at the con-
centration of 15 nM are showed after normalization: the slope of curves
for ST8199AA1 and ST8200AA1 clearly demonstrates that these two
Abs associate more slowly to the antigen (dashed region).
2.7. Immunoreactivity
Tenascin-specific ELISA was used to test the immunoreactivity of
conjugates compared to Tenatumomab. As shown in Fig. 2, ST8198AA1
resulted the most preserved derivative, although its residual im-
munoreactivity was reduced to about 50%. More in detail, residual
immunoreactivity was 52% for Tenatumomab-DOTAMA (ST8198AA1),
26% for Tenatumomab-Bn-DOTA (ST8199AA1) and 22% for Tenatu-
momab-Bn-CHX-A″-DTPA (ST8200AA1) (mean of three experiments).
2.8. 111In radiolabeling of Tenatumomab-DOTAMA
Radiolabeling efficiency by iTLC of ST8198AA1 conjugate was
77.0% and 47.2% for 1:0.12 and 1:0.7 (DOTAMA: 111In atoms) re-
spectively. The analysis repeated in the presence of a DTPA excess,
which is challenging low affinity bonds, resulted of 58.5% and 23.5%,
for 1:0.12 and 1:0.7 (DOTAMA: 111In atoms), respectively. Based on
both analyses, the best conjugate appeared to be the one with
(DOTAMA: 111In atoms) 1:0.12.
The reaction mixture was then purified on a PD-10 column and
relevant fractions re-analyzed by iTLC, showing that most activity of
the radiolabeled conjugate was eluted in the fractions 7–9 (Table 3).
2.9. Stability of radioconjugates
Preliminary stability of the radiolabeled material under the in-
tended storage condition of investigational lots was confirmed by iTLC
after 24 h at +4 °C (Table 4).
3. Conclusions
Tenascin-C, a hexameric glycoprotein preferentially expressed in
malignant solid and hematological tumors and related to tumor neo-
vascularization, anti-adhesive and immunosuppressive activities, re-
presents an attractive candidate for antibody mediated therapy.
Tenatumomab (ST2146), a murine monoclonal antibody that re-
cognizes the extra-cellular matrix protein Tenascin-C, was originally
imagined for delivering radionuclide therapy to tumors. The 131Iodine-
Tenatumomab has been investigated in clinical trials in Tenascin-C
positive cancer patients. Here we describe the chemical conjugation of
chelator moieties to Tenatumomab and the preliminary characteriza-
tion of the related derivatives as candidates for prospective theranostic
uses.
The conjugation reaction of three different bifunctional chelators to
Tenatumomab and then the complexation of the resulting antibody-
chelator conjugates with different metal ions of interest for imaging or
therapeutic applications, were screened. The results indicated that
NHS-DOTA is the most efficient moiety that reacts preferentially on the
heavy chain of the antibody. Moreover, the Tenatumomab-DOTAMA
conjugate formed the complexes with Y(III), Lu(III) or Cu(II) in high
yield both in the presence of excess of metal ion and in excess of
Table 2
Yields of the complexation of Tenatumomab-chelator conjugates with In3+, Y3+, Cu2+ and Lu3+ (ratio MAb-chelator/metal ion 1:0.1) in two different buffers (0.2M
acetate buffer, pH 5 and 0.2M Hepes buffer, pH 6.8).
Entry Acetate buffer 0.2M (pH 5.0) Yield (%) HEPES buffer 0.2M (pH 6.8) Yield (%)
1a In(DOTAMA) 44.0 ± 2.7 In(DOTAMA) 46.5 ± 2.4
2a [In(Bn-CHX-A″-DTPA)]2− 61.4 ± 5.7 [In(Bn-CHX-A″-DTPA)]2− 73.5 ± 6.8
3a [In(Bn-DOTA)]− 44.6 ± 7.9 [In(Bn-DOTA)]− 65.2 ± 7.0
4a Y(DOTAMA) 27.3 ± 0.7 Y(DOTAMA) 91.2 ± 8.7
5a [Y(Bn-CHX-A″-DTPA)]2− 77.5 ± 3.4 [Y(Bn-CHX-A″-DTPA)]2− 86.2 ± 0.8
6a [Y(Bn-DOTA)]− 74.7 ± 7.7 [Y(Bn-DOTA)]− 72.4 ± 7.1
7a Lu(DOTAMA) 36.8 ± 0.1 Lu(DOTAMA) 16.9 ± 6.8
8a [Lu(Bn-CHX-A″-DTPA)]2− 56.6 ± 2.9 [Lu(Bn-CHX-A″-DTPA)]2− 82.6 ± 7.0
9a [Lu(Bn-DOTA)]− 22.3 ± 1.9 [Lu(Bn-DOTA)]− 0.2 ± 0.1
10a Cu(DOTAMA) 53.1 ± 0.5 Cu(DOTAMA) 74.7 ± 7.3
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antibody-chelator conjugates. A stability test in physiological condi-
tions showed that the complexes are stable with negligible release of
free metal from the chelator.
Monoclonal antibodies are entering clinical trials and being ap-
proved in record numbers with over 570 antibodies at various devel-
opment stage.20 Nevertheless, among radiolabeled antibodies only
ibritumomab survived on the market and the percentage of
investigational radiolabeled antibodies is very low because of intrinsic
logistic/technological difficulties in the development of such ther-
apeutics. However, radionuclide therapy of tumors is particularly ap-
pealing because of the high direct therapeutic potential of irradiation
and because of the emerging role of irradiation in unmasking tumor
cells to the immune system thus adding efficacy to emerging im-
munotherapeutic approaches like those based on check point inhibitor
antibodies.21
From the ibritumomab experience, it emerged the value of radio-
immunotherapy for hematological tumors and the usefulness of dosi-
metry to model pharmacokinetic and optimize treatment.22
Unfortunately, radioimmunotherapy of solid tumors is much chal-
lenging because such tumors are much more radioresistant than he-
matological and less accessible to large molecules. Moreover, both solid
and hematological tumors exhibit the problem of unpredictable level of
circulating antigens that compete with tumor-associated and affect ef-
ficiency of tumor targeting as well as off-target accumulation of
radioactivity due to sinking of immune-complexes in liver and spleen.
Therefore, personalized treatments based on pre-therapeutic imaging is
highly sought and made possible by theranostic approaches, which are
based on the use of different radionuclides optimized for imaging or
therapeutic purposes. In conclusion, we believe that Tenatumomab-
DOTAMA is an improved version of previously clinically investigated
forms of Tenatumomab because it could allow to perform pre-treatment
imaging and dosimetry evaluations finally leading to personalized
therapeutic treatments of tenascin expressing tumors.
4. Experimental part
4.1. Materials and methods
All chemicals were purchased from Sigma-Aldrich or Alfa Aesar unless
Fig. 1. A: ka1 values for Tenatumomab (ST2146),
ST8198AA1, ST8199AA1 and ST8200AA1 (first
column) and ratios of Tenatumomab ka1 value to
derived antibodies ka1 values (second column). B:
normalized sensorgrams for Tenatumomab,
ST8198AA1, ST8199AA1 and ST8200AA1 tested at
15 nM; dashed region highlights differences in as-
sociation kinetics of the four antibodies.
Fig. 2. Immunoreactivity of conjugates (ST8198AA1, ST8199AA1,
ST8200AA1) as compared to Tenatumomab, tested by Tenascin-C specific
ELISA. Detection through anti-mouse IgG-PA antibody and pNpp substrate
addition. Optical density at 405 nm measured by spectrophotometer. Result are
the mean (± SD) of three independent experiments.
Table 3
Percent of radiolabeled conjugate Tenatumomab-DOTAMA and free metal in
PD-10 fractions by iTLC.
Fraction Antibody coniugated metal Free metal
6 99.72% 0.28%
7 99.59% 0.41%
8 98.43% 1.57%
9 83.96% 16.04%
10 39.50% 60.50%
11 25.01% 74.99%
12 21.46% 78.54%
Table 4
Percent of radiolabeled conjugate Tenatumomab-DOTAMA and free metal in
PD-10 fractions by iTLC, after 24 h at +4 °C.
Fraction Antibody coniugated metal Free metal
7 99.42% 0.58%
8 98.38% 1.62%
10 40.27% 59.73%
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otherwise stated and were used without further purification. p-SCN-Bn-
DOTA (S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetra-
acetic acid), NHS-DOTA, p-SCN-Bn-NOTA (2-S-(4-Isothiocyanatobenzyl)-
1,4,7-triazacyclononane-1,4,7-triacetic acid) and p-SCN-Bn-CHX-A″-DTPA
([(R)-2-Amino-3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-
1,2-diamine-pentaacetic acid) were purchased from Macrocyclics Inc (US).
Tenutomomab is a monoclonal anti-tenascin antibody developed by
Alfasigma (former Sigma Tau; ST2146).
4.2. Complexation protocol for the model chelator compounds
To obtain information about their metal binding efficiency, the
model ligands were dissolved in water (1mL) and the pH was adjusted
to 6.0. An excess of 1.1M equivalents of the metals ions were added as
the following salts (YCl3; Lu(NO3)3; GdCl3; InCl3 and CuCl2) and the pH
was brought back to 6. The solutions were left stirring for 1 h at 37 °C
and freeze-dried. HPLC–MS analyses showed the formation of the metal
complexes except for the Cu(II) complex with Cy-Bn-DOTA as pre-
cipitation occurs as soon as the metal ion is added to the ligand (the
product also precipitated at different pH values (4.0–6.0) (HPLC-MS
analyses method: AcONH4 pH 5.5 (A)/MeOH (B): 0–3min 70% A;
3–18min dal 30% al 100% B).
4.3. Stability study of the model complexes
The model cyclohexylamine-conjugated complexes obtained
(Scheme 1S) were dissolved in 1mL PBS (pH 7.4) and left at 37 °C for
one week in a thermostatic water bath. Every 24 h HPLC analyses and
1H proton spectra (except for Gd-complexes) were performed in order
to investigate the stability of the complexes (HPLC–MS analyses
method: AcONH4 pH 5.5 (A)/MeOH (B): 0–3min 70% A; 3–18min dal
30% al 100% B).
4.4. Synthesis of the mAb-ligand conjugates
In order to optimize the conjugation conditions to bind in a range of
1.5–2.0 ligands for mAb, the effects of mAb/ligand molar conjugation
ratio, reaction time, temperature, pH, and reaction buffer were studied.
First of all, the antibody was dialyzed overnight at 4 °C with 0.1M
NaHCO3 buffer, pH 7.4, using a 14M WCO membrane in order to
change the buffer and to eliminate small interfering molecules. Each
ligand was solubilized in DMSO just before starting the reaction at a
concentration of 10mM and added to the reaction mixture using 1:10
or 1:20 mAb/ligand molar ratios.
Depending on the ligand, the conjugation reaction was performed in
0.1M NaHCO3 buffer, pH 7.4, with 10-fold molar excess for NHS-
DOTA, and 20-fold molar excess for p-SCN-Bn-DOTA, and p-SCN-Bn-
CHX-A″-DTPA.
The reaction time was 45min for NHS-DOTA and 2 h for the other
two ligands, at room temperature under gentle shaking.
The conjugation mixture was dialyzed in a dialysis membrane with
a molecular cut-off value of 14 kDa against 0.1M NaHCO3 buffer, pH
7.4 with two buffer changes to remove the unconjugated ligands. The
concentration of each Tenatumomab derivative was determined spec-
trophotometrically at 280 nm (OD280nm/1.35). Few microliters of the
reaction products and of the starting naked antibody were desalted for
MALDI mass spectrometry analysis.
4.5. mAb-chelator conjugates analysis by MALDI
As described above, in the Results and Discussion Section 2.3, native
and reduced Tenatumomab as well as its conjugated derivatives were
analyzed by MALDI mass spectrometry, in order to get information on
the localization of the chelating agent. The results obtained showed
unchanged molecular weight for the light chain of both the naked and
the NHS-DOTA conjugated product, while for the NCS derivatives also a
molecular species with increased molecular weight was observed (Fig.
S3). While for the heavy chain of all the compounds analyzed, the mass
spectra obtained showed a difference in molecular weight attributable
to the presence of one molecule of chelating agent conjugated except
for Tenatumomab-DOTAMA that showed a difference of about 500 Da
(52.4 vs. 51.9 kDa), corresponding to two DOTA residues (Fig. S4). All
these data suggest that conjugation reactions occurred preferentially on
the heavy chain of the antibody with the sole exception of iso-
thiocyanate where a conjugation also to the light chain was possible as
shown by the peaks at about 48 kDa, attributable to the [2M+H]+ of
the light chain portion.
4.6. Complexation protocol of Tenatumomab-conjugates with metals ions
2mg of each conjugates antibody-chelator (Tenatumomab-
(DOTAMA), Tenatumomab-(Bn-DOTA) and Tenatumomab-(Bn-CHX-
A″-DTPA)) dissolved in PBS pH 7.4, (+NaN3 0.05%), were exchanged
three times with the appropriate buffer (acetate buffer pH 5 or Hepes
buffer pH 6.8) using Vivaspin concentrators (cutoff 10 kDa) and ad-
justing the final volume to 1mL.
For preparations of the complexes two different molar ratios were
used: 1:5 (Tenatumomab-conjugates:metal ions), to evaluate the max-
imum binding capacity, and 1:0.1 (Tenatumomab-conjugates:metal
ions) to evaluate the binding efficiency in possible future conjugations
with radiometals at low specific activity (for diagnostic use).
Both the metal-ions amounts (5 eq. or 0.1 eq.) were evaluated, with
the following salts: YCl3, Lu(NO3)3, InCl3, and, only for DOTAMA CuCl2,
and the complexations were left stirring for 2 h at 37 °C. Moreover, for
the molar ratio 1:5 the complexations was carried out in 0.2M acetate
buffer pH 5.0 (we have used acetate buffer as a suitable buffer, already
reported on numerous literature articles, for the complexation of li-
gand-antibody conjugates,17 while for the molar ratio 1:0.1 the com-
plexation was performed also in 0.2M hepes buffer pH 6.8.
The yield of the complexation reaction was determined by means of
inductively coupled plasma-mass spectrometry (ICP-MS, Thermo
Optek X Series 2) after microwave mineralization of the samples. For
this purpose, acid digestion of the conjugates in 800 μL of HNO3 70%
w/w and 200 μL of hydrogen peroxide 35% w/w in water were per-
formed in quartz cuvettes. The cuvettes were then introduced into a
closed vessel in the microwave oven, where a temperature-controlled
microwave heating (200 °C) was applied for 45min (microwaves
power=1200W, Milestone Start D with internal temperature sensor).
4.7. Stability study of Tenatumomab-conjugates complexes
The stability was determined only for the Tenatumomab-con-
iugates:metal ions ratio 1:5.
For this purpose, the metal complexes were exchanged back to PBS
buffer (+NaN3 0.05%) (pH 7.4) through Vivaspin concentrators (cut-
off 10 kDa) and left at 37 °C for one week in a thermostatic water bath.
Every 24 h, the complexes were washed two times with PBS buffer
(+NaN3 0.05%) using Vivaspin concentrators (cut-off 10 kDa) and
adjusting the final volume to 1mL. The buffer collected during these
washings were freeze dried and then mineralized by dissolving in nitric
acid and heating at 120 °C for one night. Then, the solutions were di-
luted with water to obtain a final 1% (v:v) nitric acid concentration and
finally analyzed by ICP-MS.
4.8. SEC-HPLC analysis
Stability of ST8199AA1, ST81998AA1 and ST8200AA1 was also
investigated by SEC-HPLC analysis, after incubation of the conjugates in
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PBS at 37 or 56 °C up to 24 h. Molecular integrity was then evaluated by
size exclusion chromatography in comparison with unconjugated
Tenatumomab.
50 µg of each sample were loaded on a TSKgel G3000SWX; phase
diol, L× I.D. 30 cm×7.8mm, 5 μm particle size TOSOH BIOSCIENCE
(SIGMA) #0008541. Mobile phase of 100mM phosphate buffer solu-
tion (pH 7.0), 300mM NaCl/Acetonitrile (90:10), at a flow rate of 1ml/
min. Detection by 280 nm absorbance.
4.9. Surface plasmon resonance study on Tenatumomab and
Tenatumomab-conjugates complexes
All experiments were performed with a Biacore T200 (GE
Healthcare). Tenascin-C was immobilized on CM5 sensor chips (GE
Healthcare) according to standard amino coupling procedure: one flow
cell surface was activated with EDC/NHS (GE Healthcare Amine
Coupling Kit) and then, Tenascin (82 µg/mL in 10mmol/L sodium
acetate brought to pH 2.3 with HCl) was injected; capping of unreacted
sites was achieved by flowing ethanolamine (GE Healthcare Amine
Coupling Kit) to gain a final immobilization responses of about 790 RU.
Another flow cell of the same chip was subjected to a blank im-
mobilization to use it as reference cell (activation with EDC/NHS and
capping of activated sites with ethanolamine without flowing
Tenascin). Tenatumomab and derivatives ST8198AA1, ST8199AA1 and
ST8200AA1 were flowed at 20 µL/min in both flow cells at seven
concentration ranging from 0.45 nM to 30 nM in running buffer HBS-EP
+ (GE Healthcare) for a contact time of 240 s; after that only running
buffer was flowed in both cells for a dissociation time of 1200 s and
then the two surfaces were regenerated by flowing NaOH 50mM at
20 µL/min for 30 s. Sensorgrams obtained by subtracting signal from
the reference cell were analyzed by BiaEvaluation 1.0 software
(Supporting information Figs. S6–S9 and Table S1).
4.10. Immunoreactivity (enzyme-linked immunosorbent assay) (ELISA)
MAXISORP 96-well plates (Nunc) were coated overnight at 4 °C
with 100 µL/well of Tenascin-C (TG33) [0.5 µg/mL]. After blocking
with 300 µL/well of PBS+ 1%BSA for 1.30 h, plates were washed with
PBS 0.1% Tween 20 and incubated at room temperature with serial
dilutions of standard curve of samples starting from 8 ng/mL (8 serial
dilutions in blocking solution).
After washings, anti-mouse IgG-PA antibody (Sigma A2429), diluted
1:1000 in PBS 0.1% Tween 20 1% BSA, was added at room temperature
for 1 h and 30min. Plates were washed again and incubated with pNpp
for 30min at room temperature, optical density at 405 nm was mea-
sured by ELISA reader (TECAN).
4.11. 111In Radiolabeling of Tenatumomab-DOTAMA
Tenatumomab-DOTAMA (ST8198AA1) was radiolabeled with
111Indium (111In).
Briefly, 500 ng of ST8198AA1 in 0.5 mL of 0.2M HEPES pH 6.8,
were incubated with 1.5MBq, or 8.9MBq of radiometal (corresponding
to about 1:0.12 and 1:0.70 chelator:radiometal atoms), 2 h at room
temperature. Radiolabeling yield was tested by iTLC and then the an-
tibody-radiometal conjugate purified from unreacted 111In on PD-10
columns, collecting 0.5mL fractions.
Interesting fractions were further tested by iTLC to monitor stabi-
lity.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bmc.2019.05.047.
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